The journey from scientific discovery to patient benefit is often long and uncertain. But in recent years, lipid nanoparticles (LNPs) have emerged as a key enabler for accelerating the clinical translation of innovative therapies, including mRNA, proteins, peptides, and gene-editing tools.
At DIVERSA, we are designing next-generation nanoparticles that make this transition faster, safer, and more scalable, turning promising molecules into real-world treatments.
Bridging innovation and application
Academic labs and biotech companies are constantly developing novel therapeutic payloads, yet many promising candidates fail to progress beyond the lab due to:
- Lack of efficient delivery systems,
- Poor stability in biological environments,
- And challenges in scalability and regulatory compliance.
LNPs solve many of these hurdles by offering:
- High biocompatibility and biodegradability,
- Versatile cargo capacity (mRNA, proteins, siRNA, CRISPR, etc.),
- Controlled release profiles, and
- Compatibility with clinical-grade manufacturing processes.
The advantage of DIVERSA: translation-oriented design
At DIVERSA, we focus on designing nanoparticles for clinical translation from day one. This means:
- Using safe-by-design lipid components with excellent regulatory track records,
- Prioritizing scalable, reproducible manufacturing techniques,
- And integrating quality-by-design (QbD) principles into nanoparticle development.
Our platform is modular, allowing rapid adaptation for:
- Different therapeutic payloads
- Target tissue tropism,
- And combination therapies (e.g. mRNA + protein, or small molecules + targeting ligands).
For preclinical to clinical: built for translation
At DIVERSA, we are deeply rooted in research and development, but we never lose sight of the clinic. Our lipidic nanoparticles are designed with translation in mind, combining scientific flexibility with features that support regulatory and manufacturing readiness.
We collaborate closely with key partners to ensure a seamless transition from preclinical research to early clinical trials. Together, we support the full translational path.
- Preclinical validation with expert researchers in the targeted disease and CROs.
- Scalable production with GMP-ready design.
- Regulatory support for IND/IMPD documentation.
- Clinical implementation with trusted partners.
By integrating translation into every step of our innovation process, we aim to develop promising therapies from bench to bedside, faster and smarter.
A future where translation is built in
In a world of rapid biomedical innovation, success belongs to platforms that can adapt and deliver. LNPs are no longer just delivery vehicles, they are strategic tools for translational success.
We work to make sure science has a path to patients.
Visit www.diversatechnologies.com or send an email to info@diversatechnologies.com to explore our solutions.
References
Internal References
- Lipid nanoparticles: advancing your research, no matter which area you work in
- Small molecules: towards clinical development
- Overcoming regulatory hurdles in clinical translation of nanomedicine
- How nanotechnology is shaping the future of personalized medicine
External References
- Kulkarni, J. A., Witzigmann, D., Chen, S., Cullis, P. R., & Van Der Meel, R. (2019). Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Accounts of chemical research, 52(9), 2435-2444. org/10.1021/acs.accounts.9b00368
- Jung, H. N., Lee, S. Y., Lee, S., Youn, H., & Im, H. J. (2022). Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging. Theranostics, 12(17), 7509. org/10.7150/thno.77259
- Stamoula, E., Vavilis, T., Dardalas, I., & Papazisis, G. (2025). Good Manufacturing Practices and Upscaling of mRNA Vaccine Production. Trends in mRNA Vaccine Research, 177-200. org/10.1002/9783527838394.ch6
- Svenson, S. (2012). Clinical translation of nanomedicines. Current Opinion in Solid State and Materials Science, 16(6), 287-294. org/10.1016/j.cossms.2012.10.001
